Drugs / ICT-121
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02049489 | Dec 2013 → Mar 2017 | glioblastoma | Precision Life Sciences Group | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ICT-121 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02049489 ↗ |
| Known as | ICT-121 DC vaccine | “Biological: ICT-121 DC vaccine” NCT02049489 ↗ |
| Modality | Vaccine | “ICT-121 dendritic cell (DC)vaccine” NCT02049489 ↗ |